Psilocybin didn't create disorder in the brain — it created a different kind of order

Key Findings

🌲 Oregon's Real-World Psilocybin Program Gets Its First Safety Data

• A new study in JAMA Network Open examined outcomes from Oregon's state-regulated psilocybin services — one of the first datasets from a legal, non-clinical psilocybin program outside a research trial.
• The findings address a gap that lab studies can't fill: what happens when psilocybin moves from controlled trials into regulated public access, with real facilitators and real clients.

⚡ Ketamine Quiets the Brain's Rumination Loop — Briefly

• In a randomized, double-blind, placebo-controlled fMRI study of 75 healthy adults, ketamine acutely reduced the activity of a brain network pattern linked to rumination — a hybrid configuration involving the default mode and frontoparietal networks.
• The effect was dose-sensitive: people who ruminated more showed larger reductions. The catch: it fully reversed within 24 hours, and a drug that blocks glutamate release nominally blunted the effect, pointing to glutamate as a partial mechanism.

🔬 Those "Legal LSD" Analogs? They're Mostly Just Converting to LSD

• Researchers tested four gray-market LSD analogs (1A-LSD, 1P-LSD, 1B-LSD, 1CP-LSD) in rats. All four had weaker serotonin receptor binding than LSD — yet all produced LSD-like behavioral effects. Blood samples revealed why: the compounds were metabolically converting to LSD in vivo.
• One exception: LSZ, a diethylamide-substituted analog, showed LSD-like receptor affinity on its own and wasn't converting. Individual variation in metabolism could mean dramatically different effects across people.

💊 What Actually Makes a Psychedelic a Psychedelic?

• Over 200 participants rated their subjective experiences with psilocybin, ketamine, and MDMA on a Delphi-generated scale. Factor analysis and machine learning cleanly separated the three: psilocybin was defined by visions and psychological insight, ketamine by dissociation, and MDMA by pro-social and loving feelings.
• The researchers argue psilocybin is the exemplar psychedelic — and that the defining feature of a psychedelic state is the combination of visions and insight, not altered consciousness broadly.

🔊 Ultrasound Can Supercharge Ketamine's Brain Effects — In Rats

• A preprint describes SonoKet: ketamine loaded into sound-activated liposomes that release their payload only when focused ultrasound hits a specific brain region. In awake rats, ultrasound alone didn't shift neurotransmitter levels much — but combining it with SonoKet produced glutamate, GABA, and serotonin increases comparable to doses more than 13 times higher than what was injected.
• The goal is precision: therapeutic effects in a targeted region, with less systemic exposure driving dissociation and abuse potential.

📋 Psychedelic Therapy Research Has a Methodology Problem

• A scoping review mapped how psychedelic-assisted therapy (PAT) studies actually measure what they're studying — screening, acute experience, integration, outcomes, safety — and found significant fragmentation across all of it.
• Without standardized frameworks for evaluation, comparing results across trials is difficult, and understanding which components of PAT drive which outcomes remains largely unresolved.